DE3839639A1 - USE OF TNF IN THE TREATMENT OF SKIN DISEASES - Google Patents
USE OF TNF IN THE TREATMENT OF SKIN DISEASESInfo
- Publication number
- DE3839639A1 DE3839639A1 DE3839639A DE3839639A DE3839639A1 DE 3839639 A1 DE3839639 A1 DE 3839639A1 DE 3839639 A DE3839639 A DE 3839639A DE 3839639 A DE3839639 A DE 3839639A DE 3839639 A1 DE3839639 A1 DE 3839639A1
- Authority
- DE
- Germany
- Prior art keywords
- tnf
- treatment
- skin diseases
- inflammatory skin
- preparations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
TNF-α und TNF-β sind bereits seit längerer Zeit bekannt. Sie wirken cyto toxisch und zeigen ein breites Spektrum an Aktivitäten (Lymphokines 14, 203-223 (1987)).TNF- α and TNF- β have been known for a long time. They are cyto-toxic and show a broad spectrum of activities (Lymphokines 14, 203-223 (1987)).
Es wurde nun gefunden, daß sich TNF zur Behandlung von Hauterkrankungen eignet.It has now been found that TNF is used to treat skin disorders is suitable.
Gegenstand der Erfindung ist die Verwendung von TNF bei der Behandlung von entzündlichen Hauterkrankungen.The invention relates to the use of TNF in the treatment of inflammatory skin diseases.
Gegenstand der Erfindung sind weiter äußerlich applizierbare Arzneimittel zubereitungen, die TNF enthalten.The invention further relates to medicaments which can be applied externally preparations containing TNF.
Der Begriff "TNF" schließt TNF-α (= Tumornekrosefaktor) und TNF-β (= Lymphotoxin) sowie deren Muteine ein. Solche Muteine sind beispiels weise beschrieben in EP 1 64 965, EP 1 68 214, EP 2 05 038, EP 2 51 037, WO 86/02 381 und DE 36 20 656.The term "TNF" includes TNF- α (= tumor necrosis factor) and TNF- β (= lymphotoxin) and their muteins. Such muteins are described, for example, in EP 1 64 965, EP 1 68 214, EP 2 05 038, EP 2 51 037, WO 86/02 381 and DE 36 20 656.
Als entzündliche Hauterkrankung kommt insbesondere atopische Dermatitis in Betracht.Atopic dermatitis, in particular, is an inflammatory skin disease Consider.
Als äußerlich applizierbare Arzneimittelzubereitungen eignen sich Pulver, Lösungen, Lotionen, Salben, Cremes oder Sprays. Diese können mit den üblichen galenischen Hilfsmitteln wie Konservierungsmitteln, Lösungsmitteln und Treibgasen verarbeitet sein (vgl. H. Sucker et. al.: Pharmazeutische Technologie, Thieme-Verlag, Stuttgart 1978). Die so erhaltenen Applikationsformen enthalten den Wirkstoff normalerweise in einer Menge von 10-5 bis 10-6 Gewichtsprozent. Die so erhaltenen Zubereitungen werden in der Regel 2-3mal täglich auf die entzündete Hautstelle aufgetragen.Powder, solutions, lotions, ointments, creams or sprays are suitable as externally applicable pharmaceutical preparations. These can be processed with the usual pharmaceutical auxiliaries such as preservatives, solvents and propellants (cf. H. Sucker et. Al .: Pharmaceutical Technology, Thieme-Verlag, Stuttgart 1978). The application forms thus obtained normally contain the active ingredient in an amount of 10 -5 to 10 -6 percent by weight. The preparations obtained in this way are usually applied to the inflamed area of skin 2-3 times a day.
In üblicher Weise wird eine Salbe folgender Zusammensetzung hergestellt:An ointment of the following composition is produced in the usual way:
49,0 g Wasser enthaltend 1 mg TNF-α
3,0 g Wollwaschalkohol
0,25 g Cetylsterarylalkohol
47,55 g weiße Vaseline
0,2 g p-Hydroxybenzoesäurepropylester
49.0 g water containing 1 mg TNF- α
3.0 g of wool washing alcohol
0.25 g cetylsteraryl alcohol
47.55 g of white petroleum jelly
0.2 g propyl p-hydroxybenzoate
In üblicher Weise wird eine Creme folgender Zusammensetzung hergestellt:A cream of the following composition is produced in the usual way:
67,0 g Wasser enthaltend 1 mg TNF-β
8,0 g Cetylstearylalkohol
3,5 g polyethoxyliertes hydriertes Ricinusöl
15,3 g dickflüssiges Paraffin
6,0 g weiße Vaseline
0,2 g p-Hydroxybenzoesäurepropylester67.0 g water containing 1 mg TNF- β
8.0 g cetylstearyl alcohol
3.5 g polyethoxylated hydrogenated castor oil
15.3 g of viscous paraffin
6.0 g of white petroleum jelly
0.2 g propyl p-hydroxybenzoate
Claims (3)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3839639A DE3839639A1 (en) | 1988-11-24 | 1988-11-24 | USE OF TNF IN THE TREATMENT OF SKIN DISEASES |
EP89913085A EP0445178A1 (en) | 1988-11-24 | 1989-11-21 | Use of tnf in the treatment of skin diseases |
PCT/EP1989/001412 WO1990005532A1 (en) | 1988-11-24 | 1989-11-21 | Use of tnf in the treatment of skin diseases |
JP2500042A JPH04501720A (en) | 1988-11-24 | 1989-11-21 | Use of TNF in the treatment of skin diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3839639A DE3839639A1 (en) | 1988-11-24 | 1988-11-24 | USE OF TNF IN THE TREATMENT OF SKIN DISEASES |
Publications (1)
Publication Number | Publication Date |
---|---|
DE3839639A1 true DE3839639A1 (en) | 1990-05-31 |
Family
ID=6367784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE3839639A Withdrawn DE3839639A1 (en) | 1988-11-24 | 1988-11-24 | USE OF TNF IN THE TREATMENT OF SKIN DISEASES |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0445178A1 (en) |
JP (1) | JPH04501720A (en) |
DE (1) | DE3839639A1 (en) |
WO (1) | WO1990005532A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5190750A (en) * | 1990-03-09 | 1993-03-02 | Asahi Kasei Kogyo Kabushiki Kaisha | Methods for the treatment of demyelinating disease, uveitis, or graft-versus-host disease using tnf |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU189251B (en) * | 1982-04-07 | 1986-06-30 | Asahi Kasei Kogyo Kk,Jp | Process for stabilizing tumor necrosis factor |
DE3631413A1 (en) * | 1986-09-16 | 1988-03-24 | Knoll Ag | THERAPEUTIC SYSTEM FOR LOCAL APPLICATION OF PHARMACEUTICAL ACTIVE SUBSTANCES |
US4929442A (en) * | 1986-09-26 | 1990-05-29 | Exovir, Inc. | Compositions suitable for human topical application including a growth factor and/or related materials |
-
1988
- 1988-11-24 DE DE3839639A patent/DE3839639A1/en not_active Withdrawn
-
1989
- 1989-11-21 EP EP89913085A patent/EP0445178A1/en not_active Withdrawn
- 1989-11-21 JP JP2500042A patent/JPH04501720A/en active Pending
- 1989-11-21 WO PCT/EP1989/001412 patent/WO1990005532A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1990005532A1 (en) | 1990-05-31 |
EP0445178A1 (en) | 1991-09-11 |
JPH04501720A (en) | 1992-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3856018T2 (en) | Use of a disaccharide polysulfate-aluminum compound for the manufacture of a medicament for the treatment of HÄMORRHOIDEN and for wound healing | |
DE69733086T2 (en) | PHARMACEUTICAL COMPOSITIONS WHICH CONTAIN KUUU NUTS OIL | |
DE69520041T2 (en) | MEDICINAL PRODUCTS BASED ON A SYNERGISTIC MIXTURE OF METRONIDAZOLE AND CLINAMICIN | |
DE69731610T2 (en) | ORAL ADMINISTRATION OF EFFECTIVE QUANTITIES OF HYALURONIC ACID | |
DE3413052A1 (en) | PHARMACEUTICAL PREPARATION AND THE USE THEREOF FOR TREATING SKIN DISEASES | |
DE69027220T2 (en) | COMPOSITION AND METHOD FOR TREATING PAINFUL INFLAMMABLE OR ALLERGIC DISEASES | |
DE19737348C2 (en) | Pharmaceutical composition containing clindamycin and clotrimazole | |
DE69619052T2 (en) | Solid, anhydrous, pharmaceutical preparations for vaginal use | |
EP0133151A2 (en) | Skin ointment | |
WO1989006962A1 (en) | Silver sulfadiazine-containing agent for topical external therapy | |
DE3011437A1 (en) | PHARMACEUTICAL AGENT FOR HEALING INFLAMMABLE AND / OR DEGENERATIVE AND / OR ATROPHIC MUSCULAR DISEASES | |
DE69730214T2 (en) | COMPOSITION AND METHOD FOR THE TREATMENT OF HERPES SIMPLEX | |
DE69303305T2 (en) | Means of treating chronic fatigue | |
DE3443242A1 (en) | Glycyrrhizin and a medicament containing an active compound | |
DE60206270T2 (en) | COMPOSITIONS CONTAIN THYLAKOIDS FOR MODULATING INFLAMMATION | |
DE3839639A1 (en) | USE OF TNF IN THE TREATMENT OF SKIN DISEASES | |
DE69424679T2 (en) | COMPOSITION FOR TREATING OR PREVENTING HERPES | |
EP0697878B1 (en) | New use of equisetum | |
DE2720420A1 (en) | COMBINATION OF ACTIVE INGREDIENTS AGAINST SUNNYTHEM AND MEDICINAL PRODUCT CONTAINING THIS | |
DE3830333C1 (en) | Pharmaceutical composition for the treatment of the eruption caused by herpes viruses | |
WO1996033707A1 (en) | Topical preparation for promoting muscular development | |
DE68905788T2 (en) | LOCAL MEDICINAL PRODUCTS CONTAINING TICLOPIDINE. | |
DE3633651C2 (en) | ||
DE69716769T2 (en) | PREPARATIONS FOR THE TREATMENT OF BURNS AND EXTERNAL ULCERA AND METHOD FOR THE PRODUCTION THEREOF | |
CH677878A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8130 | Withdrawal |